Clinical Trial Update: Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating a quad-therapy regimen (liposomal doxorubicin/Myocet, paclitaxel, pertuzumab, and trastuzumab) in HER2-positive breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Myocet (liposomal doxorubicin)
• PACLITAXEL (PACLITAXEL)
• Perjeta (pertuzumab)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED